|
Name |
(3R,3aR,5S,6R,7aR)-3,6,7,7-Tetramethyloctahydro-3a,6-ethanoinden-5-ol
|
| Molecular Formula | C15H26O | |
| IUPAC Name* |
2,6,6,7-tetramethyltricyclo[5.2.2.01,5]undecan-8-ol
|
|
| SMILES |
CC1CCC2C13CCC(C2(C)C)(C(C3)O)C
|
|
| InChI |
InChI=1S/C15H26O/c1-10-5-6-11-13(2,3)14(4)7-8-15(10,11)9-12(14)16/h10-12,16H,5-9H2,1-4H3
|
|
| InChIKey |
CSTOJISGDOIIDQ-UHFFFAOYSA-N
|
|
| Synonyms |
Allocedrol; allo-Cedrol; (3R,3aR,5S,6R,7aR)-3,6,7,7-Tetramethyloctahydro-3a,6-ethanoinden-5-ol; 3a,6-Ethano-3aH-inden-5-ol, octahydro-3,6,7,7-tetramethyl-, (3R,3aR,5S,6R,7aR)-; 3a,6-Ethano-3aH-inden-5-ol, octahydro-3,6,7,7-tetramethyl-, [3R-(3.alpha.,3a.beta.,5.beta.,6.beta.,7a.alpha.)]-
|
|
| CAS | NA | |
| PubChem CID | 527227 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 222.37 | ALogp: | 4.3 |
| HBD: | 1 | HBA: | 1 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 20.2 | Aromatic Rings: | 4 |
| Heavy Atoms: | 16 | QED Weighted: | 0.647 |
| Caco-2 Permeability: | -4.677 | MDCK Permeability: | 0.00001850 |
| Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.393 |
| 30% Bioavailability (F30%): | 0.682 |
| Blood-Brain-Barrier Penetration (BBB): | 0.658 | Plasma Protein Binding (PPB): | 93.30% |
| Volume Distribution (VD): | 1.185 | Fu: | 9.20% |
| CYP1A2-inhibitor: | 0.061 | CYP1A2-substrate: | 0.461 |
| CYP2C19-inhibitor: | 0.069 | CYP2C19-substrate: | 0.935 |
| CYP2C9-inhibitor: | 0.141 | CYP2C9-substrate: | 0.633 |
| CYP2D6-inhibitor: | 0.014 | CYP2D6-substrate: | 0.699 |
| CYP3A4-inhibitor: | 0.148 | CYP3A4-substrate: | 0.244 |
| Clearance (CL): | 15.422 | Half-life (T1/2): | 0.118 |
| hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.106 |
| Drug-inuced Liver Injury (DILI): | 0.031 | AMES Toxicity: | 0.02 |
| Rat Oral Acute Toxicity: | 0.073 | Maximum Recommended Daily Dose: | 0.292 |
| Skin Sensitization: | 0.253 | Carcinogencity: | 0.042 |
| Eye Corrosion: | 0.087 | Eye Irritation: | 0.774 |
| Respiratory Toxicity: | 0.875 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001893 | ![]() |
0.623 | D0L2LS | ![]() |
0.317 | ||
| ENC002267 | ![]() |
0.517 | D0V8HA | ![]() |
0.293 | ||
| ENC002110 | ![]() |
0.474 | D0Z1XD | ![]() |
0.284 | ||
| ENC003109 | ![]() |
0.474 | D0U3GL | ![]() |
0.284 | ||
| ENC002998 | ![]() |
0.474 | D0I2SD | ![]() |
0.276 | ||
| ENC003103 | ![]() |
0.433 | D0Q6NZ | ![]() |
0.267 | ||
| ENC001831 | ![]() |
0.424 | D03XOC | ![]() |
0.264 | ||
| ENC003097 | ![]() |
0.424 | D0P0HT | ![]() |
0.264 | ||
| ENC003477 | ![]() |
0.410 | D0H1QY | ![]() |
0.263 | ||
| ENC004227 | ![]() |
0.389 | D08QKJ | ![]() |
0.261 | ||